Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).
Primary Objective: To determine the 1-year treatment free remission rate after 12 cycles of combination therapy with TKIs plus ruxolitinib in subjects who have experienced molecular relapse after prior TKI discontinuation.
AMN107 (Nilotinib); Dasatinib (BMS-354825); Gleevac (Imatinib Mesylate); Imatinib Mesylate (); Nilotinib (); Ponatinib (AP24534); Rituxan (rituximab); STI571 (Imatinib Mesylate); Tasigna (Nilotinib); rituximab ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.